:format(jpeg):focal(2215x748:2225x738)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/IPXX3YHWOVCJHP6PULSVAE2I7A.jpg)
washington — The Food and Drug Administration The FDA on Thursday approved the first over-the-counter birth control pill, which will allow American women and girls to buy birth control drugs in the same aisle as aspirin and eye drops.
The agency said it authorized the over-the-counter sale of the Opill of Perrigo, which is administered once a day, which makes it the first drug of its kind to be removed from the pharmacy counter. The company won’t start shipping the pill until early next year and there will be no age restrictions on sales.
Hormone-based pills have long been the most common form of birth control in the United States, used by tens of millions of women since the 1960s. Until now, all required a prescription.
Medical societies and women’s health groups have pushed for broader access, pointing out that an estimated 45% of the 6 million annual pregnancies in the United States are unintended. Teens and girls, women of color, and people with low income report increased barriers to getting and picking up prescriptions.
Some of the challenges may include paying for a doctor’s visit, taking time off work, and finding child care.
“This is truly a transformation in access to contraceptive care,” said Kelly Blanchard, president of Ibis Reproductive Health, a nonprofit group that supported the passage. “Hopefully this will help people overcome the barriers that are out there now.”
Ireland-based Perrigo did not announce a price. Over-the-counter drugs are usually much cheaper than prescription drugs, but they are not covered by insurance.
Many common medications have transitioned to over-the-counter status in recent decades, including pain, heartburn, and allergy medications.
Perrigo submitted years of research to the FDA to show that women could understand and follow the instructions for using the pill. Thursday’s approval came despite some concerns from FDA scientists about the company’s results, including whether women with certain underlying medical conditions would understand they shouldn’t take the drug.
The FDA action only applies to Opill. It’s in an older class of birth control, sometimes called mini-pills, which contain a single synthetic hormone and generally have fewer side effects than the more popular combined hormone pills.
But women’s health advocates hope the decision will pave the way for more over-the-counter birth control options and, eventually, abortion pills to follow suit.
Having said that, FDA decision unrelated to ongoing court battles over abortion pill mifepristone. Studies in Perrigo’s FDA application began years before the Supreme Court struck down Roe v. Wade, who has disrupted access to abortion in the United States.
With some states restricting women’s reproductive rights, the FDA has faced pressure from Democratic politicians, health advocates and medical professionals to make birth control more accessible. The American Medical Association and the leading professional society of obstetricians and gynecologists endorsed Opill’s application for over-the-counter status.
An external panel of FDA advisers voted unanimously in favor of the change at a hearing in May where dozens of speakers called for approval of Opill.
Dyvia Huitron was among those who presented, explaining how she has been unable to obtain prescription contraceptives for more than three years after becoming sexually active. The 19-year-old University of Alabama student said she still isn’t comfortable getting a prescription because the school’s health system informs parents about medical tests and medications.
“My parents wouldn’t let me take the pill,” Huitron said in a recent interview. “There was a lot of cultural stigma around being sexually active before you got married.”
While she uses other forms of birth control, “I would have preferred to have birth control and use these additional methods to make sure I was as safe as possible.”
Huitron spoke on behalf of Advocates for Youth, one of dozens of groups that have pushed to make prescription birth control more accessible.
The groups helped fund some of the studies submitted for Opill and encouraged HRA Pharma, later acquired by Perrigo, to apply to the FDA.
Defenders were particularly interested in Opill because it posed fewer security concerns. The pill was first approved in the United States five decades ago, but hasn’t been marketed here since 2005.
“It has been around for a long time and we have a lot of data to support that this pill is safe and effective for use without a prescription,” said Blanchard, of Ibsis Reproductive Health.
Newer birth control pills usually combine two hormones, estrogen and progestin, which can help make periods lighter and more regular. But their use carries an increased risk of blood clots, and they should not be used by women at risk of heart problems, such as those who smoke and are over 35.
Opill is progestin-only, which prevents pregnancy by blocking sperm from reaching the cervix. It should be taken at around the same time each day to be most effective.
In its internal review published in May, the FDA noted that some women in the Perrigo study had trouble understanding the information on the drug’s label. In particular, the instructions warn that women with a history of breast cancer should not take the pill because it could stimulate tumor growth. And women who have unusual vaginal bleeding are advised to talk to a doctor first, because it could indicate a medical problem.
Perrigo executives said the company will spend the rest of the year manufacturing the pill and its packaging so it can be available in stores across the country and online early next year.
